Acutaas Chemicals Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Record revenue, volume-led: Q4 revenue hit an all-time high of ₹225 crores, driven entirely by volume growth as prices stabilized; Advanced Pharmaceutical Intermediates surged 47% QoQ on large CDMO contract introductions.
• Gross margin compressed sharply: Gross margin fell to 40% from 46% over six quarters, squeezed by price pressure, unfavorable product mix, and a contract basis shift from CIF to FOB.
• Electrolyte additives enter commercial phase: Commercial operations began in Q4 with firm orders in hand, and an MoU with the Gujarat government signals a larger joint venture build-out, though pricing has collapsed from \$42 to \$7-\$8.
• FY25 growth bet is on volume and CDMO ramp: Management guided 25% revenue growth for FY25, anchored on quarterly volume increases and a confirmed CDMO order that commercializes in H2, shifting the revenue split to 40:60.
• What to watch next quarter: Whether Baba Fine Chem customer approvals close on schedule, the pace of electrolyte additive commercial supply starting in Q2, and any gross margin stabilization toward the 21% EBITDA target.

Revenue Drivers & Product Pipeline

• API segment dominance: Advanced Pharmaceutical Intermediates grew 18% YoY and 47% QoQ to ₹190 crores, lifted by the introduction of large CDMO contracts that will ramp further in H2 FY25.
• Specialty chemicals momentum: Overall specialty grew 36% in Q4; organic specialty excluding the Baba Fine Chem acquisition grew 18%, confirming underlying demand strength.
• Apixaban trajectory: Firm demand with over 26 customer DMFs supports growth from H2 FY25, peaking in FY26-27 at generic launch, though a prior decline followed a lawsuit loss by generic manufacturers in some territories.
• Darolutamide ramp: FY25 is a qualification year with ramp-up; FY26 will be full contribution; the originator expects 3x growth from the current base to \$3 billion, and the company supplies all five intermediates.
• Lumateperone positioning: A unique, green chemistry process with better yield and cost advantage positions the company as the preferred supplier when the patent expires.
• NCE pipeline replenishment: Five to six new NCE programs are added every year, progressing from Phase 1 through Phase 3, sustaining the CDMO funnel.

Patel: "So that is where Ami Organics is always focusing on all of our products, which we are working for the generic development is likely so that when these products are coming into the market, we will be -- not be kicked out by the generic API manufacturer because our cost is not competitive."

Electrolyte Additives & New Verticals

• Commercial operations started: Manufacturing began in Q4 with firm orders received; commercial supply to customers is expected to start slowly from Q2 FY25.
• Pricing collapse, margin defense: Prices fell from \$42 to \$7-\$8, but management asserts margins are sustainable due to strong process technology and IRA-application agreements providing \$1-\$2 leverage against Chinese competitors.
• Portfolio expansion: Eight new additives were developed in the last year beyond the two commercialized earlier; samples have been approved at plant scale for six customers.
• Capacity build-out: After 2.5 years, the company decided to construct a larger-capacity plant for additives, signaling conviction in long-term demand despite current pricing.
• Electrolyte solution JV: An MoU with the Gujarat government is signed; the company is finalizing capex and the governing structure of a joint venture with a global MNC player, with an announcement expected soon.

Patel: "All these are niche areas and particularly the electrolytes additives as well as the semiconductor is a very new area, not only for us as well as for India as well. So there, we are growing very cautiously and firmly."

Margins & Profitability

• Gross margin erosion: Gross margin declined from 46% to 40% over six quarters due to price pressure from customers, a 1% hit from converting contracts from CIF to FOB basis, unfavorable product mix, and CDMO validation costs booked in Q4.
• EBITDA recovery: EBITDA margin improved 326 bps sequentially to 19.2%, driven by operating leverage and lower freight and other costs, even as gross margin compressed.
• PAT under pressure: PAT margins at 11.4% were lower due to higher depreciation and finance costs tied to the Ankleshwar expansion.
• Recovery path: Management's first target is to return to the previous base EBITDA margin of 21%, describing FY25 as a base-formation year with steady-state improvements expected from here.
• CDMO margin mix: CDMO margins are slightly compromised in toll manufacturing, but NCE programs carry very good margins, and regulated-market products earn 2-3% higher margins than the generic portfolio.

Capacity & Asset Utilization

• Ankleshwar Unit 2 progress: One production block is already commercialized for a specific customer; the other two blocks are expected to fill over the next three years with new products from innovators and existing products shifted from Unit 1 due to capacity constraints.
• Unit 1 constraints: Capacity utilization stands at 72% with no major expansion opportunities; the introduction of flow chemistry is reducing some capacity.
• Breakeven dynamics: A block reaches breakeven at roughly 30-35% utilization; management targets over 60-65% utilization across Unit 2 in the next three years.
• Asset turn expectations: Management expects 2.5-3x asset turns on a net block basis in the next 2-2.5 years after temporary suppression from capitalization, and 2-3x on all capex including Unit 2.
• Goodwill movements: Goodwill rose from ₹23 crores to ₹57 crores due to the Baba Fine Chemicals investment; prior goodwill for Ami Oncotheranostics LLC was fully provided during the year.

Acquisitions & Integration

• Baba Fine Chem sales decline: Sales declined YoY because the customer qualification process is lengthy and differs from pharma and specialty; documentation and licensing changes at the customer end are ongoing.
• Integration timeline: Integration is expected to complete in Q1 or Q2 FY25, with all customer approvals targeted to close within that window.
• Structural note: Baba Fine Chem is a partnership firm with a 35% tax rate, which affects consolidated profitability.

Balance Sheet & Capital Allocation

• Cash flow strength: Strong cash from operations of ₹125.2 crores was driven by a sharp improvement in the debtor cycle despite a difficult year.
• Equity raise plans: The company notified exchanges about a potential QIP and preferential investment; proceeds will be used for capex.
• Debt ceiling increase: The increase is for statutory compliance related to Ankleshwar expansion debt; management does not intend to hit the increased limit for at least the next two years.
• Patent strategy shift: Three process patents were granted during the quarter, reflecting a deliberate strategy to protect niche, complex products from competition early, securing a larger share when products mature and go generic.

Patel: "In the past, we were not doing that, and then we observed that after 2, 3 years, we start facing the competition from local as well as the world market. So then we decided the strategy to protect ourselves right from the beginning so that when the product gets matured and when it becomes generic, we will be having a larger pie of the cake."

Guidance & Commitments

Key Metrics